

phase of autoimmune disease. This strategy would also be useful to control undesired immune responses in bone marrow transplantation.

In conclusion, the current results indicate that by selective removal of CD4⁺ T cells, it may be possible to attenuate the CD4⁺ T cell immune responses. The technology used in the CD4-column may be applicable to adsorb other target cells, such as lymphocytes with other surface markers or other immune cells, by selecting the appropriate antibody as a ligand. By targeting other surface molecules, such as markers for activated T cells, adhesion molecules or particular T cell receptors, we may remove the pathogenic cells more efficiently.

Acknowledgments: The authors thank Dr A Tsujino for excellent technical assistance. This work was supported by a grant from the Japan Health Sciences Foundations.

REFERENCES

1. Waldmann H. Manipulation of T cell responses with monoclonal antibodies. *Ann Rev Immunol* 1990;1:1-11.
2. Goldberg D, Morel P, Chatenoud L, Boitard C. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. *J Autoimmun* 1989;4:617-30.
3. Horneff G, Burmester GR, Emmrich R, Karden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. *Arthritis Rheum* 1991;34:129-40.
4. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. *Arthritis Rheum* 1991;34:525-36.
5. Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. *J Rheumatol* 1991;18:325-7.
6. Choy EH, Chikanza IC, Kingsley GH, Panayi GS. Chimeric anti-CD4 monoclonal antibody for relapsing polychondritis. *Lancet* 1991;338:450.
7. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. *Lancet* 1991;338:321.
8. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. *Lancet* 1991;338:570-1.
9. Hiepe F, Volk HD, Apostoloff E, von Baehr R, Emmrich F. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. *Lancet* 1991;338:1529-30.
10. Hafler DA, Ritz F, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. *J Immunol* 1988;141:131-8.
11. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunological responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. *Neurology* 1986;36:777-84.
12. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. *Ann Neurol* 1994;36:183-9.
13. Hauser SL, Fosburg M, Keyv SV, Weiner HL. Lymphocytopheresis in chronic progressive multiple sclerosis: immunological and clinical effects. *Neurology* 1984;34:922-6.
14. Wucherpfennig KW, Zhang J, Witeck C et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. *J Immunol* 1994;152:5581-92.
15. Illes Z, Kondo T, Yokoyama K, Ohashi T, Tabira T, Yamamura T. Identification of autoimmune T cells among in vivo expanded CD25⁺ T cells in multiple sclerosis. *J Immunol* 1999;162:1811-7.